mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2010-584mrj-269Research ArticleСтатьиArticlesБольная хронической подагрой:комментарии к течению болезниBol'naya khronicheskoy podagroy:kommentarii k techeniyu bolezniБарсковаВ. Г.BarskovaV Gbarskova@irramn.ruEliseevM SEliseevM S-20101403201041№1 (2010)3238Copyright © Барскова В.Г., Eliseev M.S., 20102010Барскова В.Г., Eliseev M.S.Barskova V.G., Eliseev M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/269References<div><p>Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры - научно обоснованное требование улучшения трудового и жизненного прогноза больных. Науч-практич ревматол 2004;1:5-7.</p><p>Arromdee E., Michet C.J., Crowson C.S. et al. Epidemiology of Gout: Is the Incidence Rising? J Rheum 2002;29:2403-6.</p><p>Gutman A.B. The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthr Rheum 1973;16:431-45.</p><p>Барскова В.Г., Насонова В.А., Якунина И.А. и др. Ретроспективный анализ причин поздней диагностики подагры. Клин геронтол 2004;6:12-7.</p><p>Zhang W., Doherty M., Pascual-Gоmez E. et al. EULAR evidence based recommendation for the diagnosis and management of gout. Ann Rheum Dis 2005;64(Suppl. III):501.</p><p>Wallace S.L., Robinson H., Masi A.T. et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthritis Rheum 1977;20:895-900.</p><p>Arnett F.C., Edworthy S.M., Bloch D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988;31:315-24. 8.</p><p>Всероссийское научное общество кардиологов. Национальные клинические рекомендации. М., 2009;392.</p><p>Augustin R., Carayannopoulos M.O., Dowd L.O. et al. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004;279:16229-36.</p><p>Brandstatter A., Kiechl S., Kollerits B. et al. Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabetes Care 2008;31:1662-7.</p><p>Doring A., Gieger C., Mehta D. et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008;40:430-6.</p><p>Li S., Sanna S., Maschio A. et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007;3:e194.</p><p>Vitart V., Rudan I., Hayward C. et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008;40:437-42.</p><p>Wallace C., Newhouse S.J., Braund P. et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008;82:139-49.</p><p>Stark K., Reinhard W., Neureuther K. et al. Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study. PLoS ONE 2008;3:e1948.</p><p>Enomoto A., Kimura H., Chairoungdua A. et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417:447-52.</p><p>Le M.T., Shafiu M., Mu W. et al. SLC2A9 - a fructose transporter identified as a novel uric acid transporter. Nephrol Dial Transplant 2008;23:2746-9.</p><p>Барскова В.Г., Насонова В.А. Дифференциальная диагностика подагрического артрита и методы его купирования. РМЖ 2004;12(6):399-403.</p><p>Zhang W., Doherty M., Pascual E. et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1301-11.</p><p>Елисеев М.С., Барскова В.Г., Якунина И.А. и др. Диагноз подагра - противопоказание для назначения диуретиков. Фарматека 2003;5:67-70.</p><p>Kang E.H., Lee E.Y., Lee Y.J. et al. Clinical features and risk factors of postsurgical gout. Ann Rheum Dis 2008;67:1271-5.</p><p>Reinders M.K., Haagsma C.A., Jansen T.L.Th. et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Annals of the Rheumatic Diseases 2009;68:892-7.</p></div><br /><div><p>Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры - научно обоснованное требование улучшения трудового и жизненного прогноза больных. Науч-практич ревматол 2004;1:5-7.</p><p>Arromdee E., Michet C.J., Crowson C.S. et al. Epidemiology of Gout: Is the Incidence Rising? J Rheum 2002;29:2403-6.</p><p>Gutman A.B. The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthr Rheum 1973;16:431-45.</p><p>Барскова В.Г., Насонова В.А., Якунина И.А. и др. Ретроспективный анализ причин поздней диагностики подагры. Клин геронтол 2004;6:12-7.</p><p>Zhang W., Doherty M., Pascual-Gоmez E. et al. EULAR evidence based recommendation for the diagnosis and management of gout. Ann Rheum Dis 2005;64(Suppl. III):501.</p><p>Wallace S.L., Robinson H., Masi A.T. et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthritis Rheum 1977;20:895-900.</p><p>Arnett F.C., Edworthy S.M., Bloch D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988;31:315-24. 8.</p><p>Всероссийское научное общество кардиологов. Национальные клинические рекомендации. М., 2009;392.</p><p>Augustin R., Carayannopoulos M.O., Dowd L.O. et al. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004;279:16229-36.</p><p>Brandstatter A., Kiechl S., Kollerits B. et al. Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabetes Care 2008;31:1662-7.</p><p>Doring A., Gieger C., Mehta D. et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008;40:430-6.</p><p>Li S., Sanna S., Maschio A. et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007;3:e194.</p><p>Vitart V., Rudan I., Hayward C. et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008;40:437-42.</p><p>Wallace C., Newhouse S.J., Braund P. et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008;82:139-49.</p><p>Stark K., Reinhard W., Neureuther K. et al. Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study. PLoS ONE 2008;3:e1948.</p><p>Enomoto A., Kimura H., Chairoungdua A. et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417:447-52.</p><p>Le M.T., Shafiu M., Mu W. et al. SLC2A9 - a fructose transporter identified as a novel uric acid transporter. Nephrol Dial Transplant 2008;23:2746-9.</p><p>Барскова В.Г., Насонова В.А. Дифференциальная диагностика подагрического артрита и методы его купирования. РМЖ 2004;12(6):399-403.</p><p>Zhang W., Doherty M., Pascual E. et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1301-11.</p><p>Елисеев М.С., Барскова В.Г., Якунина И.А. и др. Диагноз подагра - противопоказание для назначения диуретиков. Фарматека 2003;5:67-70.</p><p>Kang E.H., Lee E.Y., Lee Y.J. et al. Clinical features and risk factors of postsurgical gout. Ann Rheum Dis 2008;67:1271-5.</p><p>Reinders M.K., Haagsma C.A., Jansen T.L.Th. et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Annals of the Rheumatic Diseases 2009;68:892-7.</p></div><br />
The authors declare that there are no conflicts of interest present.